Skip to main content

Advertisement

Table 1 VAV3 nuclear and cytoplasmic expression in relation to other tumor markers assessed by the Spearman’s rank correlation a

From: VAV3 mediates resistance to breast cancer endocrine therapy

  Nuclear VAV3, n(%) Cytoplasmic VAV3, n(%)
Score 1+ 2+ 3+ 1+ 2+ 3+
All tumors 607 (85.9) 3 (0.4) 43 (6.1) 54 (7.6) 229 (32.4) 154 (21.8) 215 (30.4) 109 (15.4)
Tumor size (>20 mm vs. ≤20 mm) Rs = −0.04, P = 0.30 Rs = 0.13, P = 0.0009
Tumor grade (1, 2 or 3) Rs = −0.09, P = 0.026 Rs = 0.16, P = 0.00007
ERα (>10% vs. ≤10%) Rs = 0.05, P = 0.20 Rs = −0.12, P = 0.002
PR (>10% vs. ≤10%) Rs = 0.06, P = 0.14 Rs = −0.15, P = 0.0002
HER2 status (positive vs. negative) Rs = 0.00, P = 0.99 Rs = 0.05, P = 0.16
Phospho-Ser167 ERα (%) Rs = 0.12, P = 0.002 Rs = −0.11, P = 0.003
Phospho-Ser305 ERα (%) Rs = 0.11, P = 0.006 Rs = −0.09, P = 0.016
PAK1 (cytoplasm 0 to 3 positivity) Rs = −0.07, P = 0.077 Rs = 0.12, P = 0.003
Phospho-Ser473 AKT (nuclear %) Rs = 0.18, P < 0.00001 Rs = −0.20, P < 0.00001
Phospho-Ser2448 mTOR (high vs. low) Rs = 0.06, P = 0.11 Rs = −0.08, P = 0.034
Phospho-Ser65 4EBP1 (cytoplasm 0 to 2 positivity) Rs = −0.15, P = 0.0001 Rs = 0.19, P < 0.00001
S6K2 (nuclear %) Rs = 0.21, P < 0.00001 Rs = −0.26, P < 0.00001
  1. aERα, Estrogen receptor α; mTOR, mammalian target of rapamycin; PR, Progesterone receptor. P < 0.05 values are statistically significant.